Condition: Gastric Cancer · Sponsor: Sun Yat-sen University
This is a randomized, controlled, multicenter phase Ⅲ study to evaluate the therapeutic efficacy of modified XELOX plus sintilimab versus standard XELOX plus sintilimab in subjects with advanced HER2-negative gastric or gastroesophageal adenocarcinoma in the first-line treatment. The primary outcome is the progression-free survival (PFS), with a planned enrollment of 540 subjects.
This description comes directly from the study's public registry record.
Ruihua Xu, MD · +86 20 87343795 · xurh@sysucc.org.cn
Feng Wang, MD, PhD · +86 20 87343795 · wangfeng@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| The Affliated Cancer Hospital of Guizhou Medical University | Guiyang, Guizhou, China | Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Not Yet Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Not Yet Recruiting |
| Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology | Wuhan, Hubei, China | Not Yet Recruiting |
| The First Affiliated Hospital of Nanchang University | Nanchang, Jiangxi, China | Not Yet Recruiting |
| The Second Hospital of Dalian Medical University | Dalian, Liaoning, China | Recruiting |
| Ruijin Hospital, Shanghai Jiaotong University School of Medicine | Shanghai, Shanghai Municipality, China | Not Yet Recruiting |
| West China Hospital of Sichuan University | Chengdu, Sichuan, China | Not Yet Recruiting |
| The Second Affiliated Hospital of Kunming Medical University | Kunming, Yunnan, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05918094